BACKGROUND: Stromal cell-derived factor-1alpha (SDF-1alpha) binding to its cognate receptor, CXCR4, regulates a variety of cellular functions such as stem cell homing, trafficking, and differentiation. However, the role of the SDF-1alpha-CXCR4 axis in modulating myocardial ischemia/reperfusion injury is unknown. METHODS AND RESULTS: In mice subjected to ischemic preconditioning, myocardial SDF-1alpha mRNA was found to be increased 3 hours later (P<0.05). Myocardial SDF-1alpha and CXCR4 mRNA and protein were found to be expressed in both cardiac myocytes and fibroblasts. SDF-1alpha production increased significantly after 1 or 4 hours of hypoxia and 18 hours of reoxygenation in cultured myocytes (P<0.05) but did not change in fibroblast cultures. In isolated myocytes, CXCR4 activation by SDF-1alpha resulted in increased phosphorylation of both ERK 1/2 and AKT and decreased phosphorylation of JNK and p38. Cultured myocytes pretreated with SDF-1alpha were resistant to hypoxia/reoxygenation damage, exhibiting less lactate dehydrogenase release, trypan blue uptake, and apoptotic cell death (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay) (P<0.05). This protective effect was blocked by the CXCR4 selective antagonist AMD3100. In vivo, administration of SDF-1alpha before 30 minutes of coronary occlusion followed by 4 hours of reperfusion decreased infarct size (P<0.05). The decrease in infarct size with SDF-1alpha administration also was blocked by AMD3100. CONCLUSIONS: We conclude that SDF-1alpha and its receptor, CXCR4, constitute a paracrine or autocrine axis in cardiac myocytes that is activated in response to preconditioning and hypoxic stimuli, recruiting the antiapoptotic kinases ERK and AKT and promoting an antiapoptotic program that confers protection against ischemia/reperfusion damage.
BACKGROUND: Stromal cell-derived factor-1alpha (SDF-1alpha) binding to its cognate receptor, CXCR4, regulates a variety of cellular functions such as stem cell homing, trafficking, and differentiation. However, the role of the SDF-1alpha-CXCR4 axis in modulating myocardial ischemia/reperfusion injury is unknown. METHODS AND RESULTS: In mice subjected to ischemic preconditioning, myocardial SDF-1alpha mRNA was found to be increased 3 hours later (P<0.05). Myocardial SDF-1alpha and CXCR4 mRNA and protein were found to be expressed in both cardiac myocytes and fibroblasts. SDF-1alpha production increased significantly after 1 or 4 hours of hypoxia and 18 hours of reoxygenation in cultured myocytes (P<0.05) but did not change in fibroblast cultures. In isolated myocytes, CXCR4 activation by SDF-1alpha resulted in increased phosphorylation of both ERK 1/2 and AKT and decreased phosphorylation of JNK and p38. Cultured myocytes pretreated with SDF-1alpha were resistant to hypoxia/reoxygenation damage, exhibiting less lactate dehydrogenase release, trypan blue uptake, and apoptotic cell death (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay) (P<0.05). This protective effect was blocked by the CXCR4 selective antagonist AMD3100. In vivo, administration of SDF-1alpha before 30 minutes of coronary occlusion followed by 4 hours of reperfusion decreased infarct size (P<0.05). The decrease in infarct size with SDF-1alpha administration also was blocked by AMD3100. CONCLUSIONS: We conclude that SDF-1alpha and its receptor, CXCR4, constitute a paracrine or autocrine axis in cardiac myocytes that is activated in response to preconditioning and hypoxic stimuli, recruiting the antiapoptotic kinases ERK and AKT and promoting an antiapoptotic program that confers protection against ischemia/reperfusion damage.
Authors: Stacey R Vlahakis; Angelina Villasis-Keever; Timothy Gomez; Maria Vanegas; Nicholas Vlahakis; Carlos V Paya Journal: J Immunol Date: 2002-11-15 Impact factor: 5.422
Authors: Hal E Broxmeyer; Lisa Kohli; Chang H Kim; Younghee Lee; Charlie Mantel; Scott Cooper; Giao Hangoc; Montaser Shaheen; Xiaxin Li; D Wade Clapp Journal: J Leukoc Biol Date: 2003-05 Impact factor: 4.962
Authors: Magda Kucia; Kacper Jankowski; Ryan Reca; Marcin Wysoczynski; Laura Bandura; Daniel J Allendorf; Jin Zhang; Janina Ratajczak; Mariusz Z Ratajczak Journal: J Mol Histol Date: 2004-03 Impact factor: 2.611
Authors: Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner Journal: Nat Med Date: 2004-07-04 Impact factor: 53.440
Authors: Anne Vroon; Cobi J Heijnen; Roel Raatgever; Ivo P Touw; Rob E Ploemacher; Richard T Premont; Annemieke Kavelaars Journal: J Leukoc Biol Date: 2004-01-02 Impact factor: 4.962
Authors: Arman T Askari; Samuel Unzek; Zoran B Popovic; Corey K Goldman; Farhad Forudi; Matthew Kiedrowski; Aleksandr Rovner; Stephen G Ellis; James D Thomas; Paul E DiCorleto; Eric J Topol; Marc S Penn Journal: Lancet Date: 2003-08-30 Impact factor: 79.321
Authors: Hongkuan Fan; Donald Wong; Sarah H Ashton; Keith T Borg; Perry V Halushka; James A Cook Journal: Inflammation Date: 2012-02 Impact factor: 4.092
Authors: Michael M Mysinger; Dahlia R Weiss; Joshua J Ziarek; Stéphanie Gravel; Allison K Doak; Joel Karpiak; Nikolaus Heveker; Brian K Shoichet; Brian F Volkman Journal: Proc Natl Acad Sci U S A Date: 2012-03-19 Impact factor: 11.205
Authors: Thomas J LaRocca; Martina Schwarzkopf; Perry Altman; Shihong Zhang; Achla Gupta; Ivone Gomes; Zikiar Alvin; Hunter C Champion; Georges Haddad; Roger J Hajjar; Lakshmi A Devi; Alison D Schecter; Sima T Tarzami Journal: J Cardiovasc Pharmacol Date: 2010-11 Impact factor: 3.105
Authors: Joshua J Ziarek; Anthony E Getschman; Stephen J Butler; Deni Taleski; Bryan Stephens; Irina Kufareva; Tracy M Handel; Richard J Payne; Brian F Volkman Journal: ACS Chem Biol Date: 2013-06-26 Impact factor: 5.100